医学
射血分数
心力衰竭
药丸
临床终点
内科学
心脏病学
脑利钠肽
临床试验
随机对照试验
心室重构
药理学
作者
Mingzheng Chang,Lei Cheng,Yaqian Shen,Ying Zhang,Zhongwen Zhang,Panpan Hao
出处
期刊:Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2019-01-01
卷期号:98 (2): e13906-e13906
被引量:12
标识
DOI:10.1097/md.0000000000013906
摘要
Abstract Background: Qishenyiqi dripping pill for chronic heart failure (CHF) remains controversial due to lack of high-quality trials. Therefore, we conduct this pooled-analysis to evaluate the efficacy and safety of Qishenyiqi in CHF patients. Methods: We searched for randomized clinical trials for Qishenyiqi dripping pill in treating CHF up to August 2018 through China National Knowledge Infrastructure (CNKI), the PubMed Database, the Wanfang Database, the China Scientific Journal Database (VIP), and the Chinese Biomedicine Literature Service System. RevMan 5.3 was used for pooled analyses. Based on the New York Heart Association (NYHA) classification, the clinical therapeutic effect was collected as the primary endpoint. Results: The efficacy and safety of Qishenyiqi combined with routine treatment significantly increased NYHA functional classification, left ventricular ejection fraction, cardiac index, and 6-minute walking test and decreased brain natriuretic peptide, left ventricular end-diastolic, and end-systolic dimensions with no obvious side effects in comparison with routine therapy alone. Conclusions: Together these results provide important insights into Qishenyiqi is effective and safe in improving ventricular remodeling and function of CHF patients. PROSPERO registration number: PROSPERO106695.
科研通智能强力驱动
Strongly Powered by AbleSci AI